Trending event
Moving Forward to the “New Normal”: The Record Investment and Fund Flows to Biotechnology Companies: What This Cycle Means to the Life Sciences Industry
Print PDFJoin Nutter and BioCentury for a panel discussion with industry leaders in biotechnology financing and investments. COVID-19 has led to a dramatic increase in activity as companies research and develop potential therapies. However, the funding has benefited other areas such as oncology, chronic diseases, CRISPR, RNA interference, and others. Panelists from venture capital firms and investment banks will discuss what they are seeing and where investments are being made throughout the industry.
Topics will include:
- The COVID-19 impact on biotechnology investing activity
- Other therapies and biotechnologies being funded
- How long investment generalists will be focused on biotech
- The current IPO window for biotechnology companies
By attending this webinar you will learn about the dynamic biotechnology funding market and the unique intersection of a novel virus, science, and business collaboration in the race to find a solution.
Speakers:
 |  |  |
| Simone Fishburn, Ph.D. Editor-in-Chief BioCentury | Sara Nayeem, M.D., MBA Partner New Enterprise Associates (NEA) | Iyona Rajkomar, MBBS, CFA Partner Pontifax |
 |  |  |
| David Schechner, MBA Managing Director JMP Group | Ram Selvaraju, Ph.D., MBA Managing Director H.C. Wainwright | Kathleen M. Williams, Ph.D. Co-chair, Life Sciences Nutter Moderator |
Event details:
Tuesday, July 28, 2020
12PM EST (9AM PST, 5PM BST)
